

Some substances may cause false results with enzymatic tests. The substances listed below were tested for all analytes. Less than 10% interference was seen at the levels shown.

Substance Concentration (mg/dL)			
Hemoglobin	125	Gemfibrozil	15
L-Dopa	0,8	Bilirubin	5
Ascorbic Acid	1	Probucol	32.5
Urea	500	Nicotinic Acid	10
Fructose	30	Clofibrate	80
Uric Acid	15	Lovastatin	4
Creatinine	30	Dipyron	10
Glutathione	1	Methotrexate	450
Cimetidine	7,5	Nitrofurantoin	2
Oxytetracycline	4	Gentisic Acid	0,5
Lactose	100	Methyl dopamine	0,5
Cysteine	2,5		

- Hematocrits between 30% and 52% do not affect results.
- Blood collection tubes with glycerol should not be used for the triglyceride test.
- Hand creams and soaps with glycerol may cause falsely high triglyceride results.
- The triglyceride test measures triglycerides and free glycerol. Free glycerol usually is less than 20 mg/dL.^{9,10}
- There may be a 6–7% difference in the glucose levels of fingerstick and venous blood.¹¹

EXPECTED VALUES

Cholesterol and Triglycerides:

The National Heart, Lung and Blood Institute issued the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) in May 2001.¹ The ATP III report presented the NCEP's updated clinical guidelines for cholesterol testing and management and described the following classifications for cholesterol and triglyceride testing:

	mg/dL	(mmol/L)	Classification
LDL cholesterol			
	<100	(<2.59)	Optimal
	100–129	(2.59–3.34)	Near optimal/above optimal
	130–159	(3.36–4.11)	Borderline high
	160–189	(4.14–4.89)	High
	190	(4.91)	Very high
Total cholesterol			
	<200	(<5.18)	Desirable
	200–239	(5.18–6.19)	Borderline high
	240	(6.22)	High
HDL cholesterol			
	<40	(<1.03)	Low
	60	(1.55)	High
Triglycerides			
	<150	(<1.69)	Normal
	150–199	(1.69–2.25)	Borderline high
	200–499	(2.26–5.64)	High
	500	(5.65)	Very high

The ATP III identified HDL cholesterol levels below 40 mg/dL (1.03 mmol/L) as associated with increased risk of coronary heart disease (CHD) in men and women.¹ A high HDL cholesterol level greater than or equal to 60 mg/dL (1.55 mmol/L) is protective and decreases CHD risk.

TC/HDL Ratio:

The ATP III report does not comment on use of the ratio of total to HDL cholesterol. Various authors have suggested that the TC/HDL ratio is the strongest lipid risk factor and can be a useful summary of CHD risk.^{12,13} A ratio of 4.5 or less is desirable. A ratio greater than 6.0 suggests a high risk of CHD.¹²

Glucose:

The American Diabetes Association has modified the criteria for fasting plasma glucose (FPG) and the diagnosis of diabetes mellitus.¹⁴

FPG <110 mg/dL	Normal fasting glucose
FPG 110 and <126 mg/dL	Intermediate fasting glucose
FPG 126 mg/dL	Provisional diagnosis of diabetes confirmed by one of the three methods below

The revised criteria for diagnosis of diabetes:

- Symptoms of diabetes plus casual plasma glucose concentration ≥200 mg/dL (11.1 mmol/L). Casual is defined as any time of day without regard to time since last meal. (The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss.)
- FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours.
- 2 hr. post glucose load ≥200 mg/dL during an oral glucose tolerance test. The test should be performed as described by WHO (World Health Organization) using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.

Any of the above abnormal glucose levels must be confirmed, on a subsequent day, by any one of the three methods listed above. When screening for diabetes, any abnormal glucose result should be referred to a physician for further follow-up.

Performance Characteristics

Total Cholesterol:		Whole Blood (heparin)
<u>Within-Run Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	10	10
\bar{X} (mg/dL) =	184	299
SD (mg/dL) =	4.6	7.3
CV (%) =	2.5	2.4

		Commercial Control Material
<u>Day-to-Day Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	20	20
\bar{X} (mg/dL) =	161	244
SD (mg/dL) =	4.3	8.6
CV (%) =	2.7	3.5

HDL Cholesterol:		Whole Blood (heparin)
<u>Within-Run Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	10	10
\bar{X} (mg/dL) =	29	46
SD (mg/dL) =	1.0	2.2
CV (%) =	3.4	4.8

		Commercial Control Material
<u>Day-to-Day Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	20	20
\bar{X} (mg/dL) =	29	46
SD (mg/dL) =	1.3	2.9
CV (%) =	4.5	6.3

Triglycerides:		Whole Blood (heparin)
<u>Within-Run Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	10	10
\bar{X} (mg/dL) =	256	362
SD (mg/dL) =	4.0	13.1
CV (%) =	1.6	3.6

		Commercial Control Material
<u>Day-to-Day Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	20	20
\bar{X} (mg/dL) =	121	276
SD (mg/dL) =	2.8	8.7
CV (%) =	2.3	3.2

Glucose:		Whole Blood (heparin)
<u>Within-Run Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	10	10
\bar{X} (mg/dL) =	103	127
SD (mg/dL) =	6.4	5.7
CV (%) =	6.2	4.5

		Commercial Control Material
<u>Day-to-Day Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	20	20
\bar{X} (mg/dL) =	103	311
SD (mg/dL) =	3.6	15.4
CV (%) =	3.5	5.0

LDL Cholesterol:		Whole Blood (heparin)
<u>Within-Run Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	10	10
\bar{X} (mg/dL) =	87	197
SD (mg/dL) =	4.3	7.5
CV (%) =	4.9	3.8

		Commercial Control Material
<u>Day-to-Day Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	20	20
\bar{X} (mg/dL) =	108	143
SD (mg/dL) =	4.6	8.4
CV (%) =	4.3	5.9

VLDL Cholesterol:		Whole Blood (heparin)
<u>Within-Run Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	10	10
\bar{X} (mg/dL) =	51	72
SD (mg/dL) =	0.8	2.6
CV (%) =	1.6	3.6

		Commercial Control Material
<u>Day-to-Day Precision</u>	<u>Level 1</u>	<u>Level 2</u>
n =	20	20
\bar{X} (mg/dL) =	24	55
SD (mg/dL) =	0.6	1.7
CV (%) =	2.5	3.1

Accuracy (Method Comparison):

The Lipid Profile-GLU cassette total cholesterol was compared with a validated method traceable to the CDC-modified Abell-Kendall reference method traceable to National Institute of Standards and Technology (NIST) standards.

The Lipid Profile-GLU cassette HDL cholesterol was compared with a validated method, utilizing dextran sulfate/magnesium chloride precipitation and enzymatic cholesterol determination. The HDL cholesterol comparison method is based on the selected method for HDL cholesterol ⁵ and has documented agreement with the CDC Reference Method.			

The Lipid Profile-GLU cassette triglyceride test was compared with a validated method, utilizing hydrolysis with lipase. The comparison method has documented agreement with a CDC Reference Method.

The Lipid Profile-GLU cassette glucose was compared with a hexokinase reference method.

The Lipid Profile-GLU cassette estimated LDL cholesterol was compared to that calculated from the above validated total cholesterol, HDL cholesterol and triglyceride methods.

The range of values tested (mg/dL) were as follows:

TC	120–300
HDL	26–85
TRG	40–500
GLU	25–575

Results:

X = Reference Method (serum)

Y = Cholestech LDX Analyzer (venous whole blood)

<u>Analyte</u>	<u>No. of Pairs</u>	<u>Slope</u>	<u>y-intercept</u>	<u>Correlation Coefficient</u>	<u>Bias at</u>
Total cholesterol	40	0.98	2.41	0.97	200 −1%
HDL cholesterol	40	0.97	0.23	0.95	35 −2%
Triglycerides	40	1.0	0.13	0.99	250 0%
Glucose	40	0.99	1.01	0.98	150 0%

References

- Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285:2486–97.
- Bachorik PS, Ross JW, for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. *Clin Chem* 1995; 41:1414–20.
- Tietz NW, ed. *Fundamentals of Clinical Chemistry*. Philadelphia, Pa: WB Saunders Co; 1987.
- Siedel J, et al. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. *Clin Chem* 1983; 29:1075–80.
- Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg²⁺ precipitation procedure for quantitation of high density-lipoprotein cholesterol. *Selected Methods for Clinical Chemistry* 1983; 10:91–9.
- Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. *Clin Chem* 1974; 20:470–5.
- Roeschlau P, Bernt E, Gruber W. Enzymatische bestimmung des gesamt-cholesterins im serum. *Z Klin Chem Klin Biochem* 1974; 12:226.
- Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clin Chem* 1982; 28:2077–80.
- Jessen RH, Dass CJ, Eckfeldt JH. Do enzymatic analyses of serum triglycerides really need blanking for free glycerol? *Clin Chem* 1990; 36:1372–5.
- Tietz NW, ed. *Clinical Guide to Laboratory Tests*. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1990.
- Blumenfeld TA, Hertelendy WG, Ford SH. Simultaneously obtained skin-puncture serum, skin-puncture plasma, and venous serum compared, and effects of warming the skin before puncture. *Clin Chem* 1977; 23/9:1705–10.
- Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. *Circulation* 1983; 67:730–4.
- Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. *Ann Intern Med* 1994; 121:641–7.
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20:1183–97.

IVD	<i>In vitro</i> diagnostic medical device
REF	Catalog number
⚠	Attention. See instructions for use
☒	Single use
🚫	Do not use if package is damaged or open
LOT	Lot number
👤	Use by:

CHOLESTECH

3347 Investment Blvd.
Hayward, CA 94545 U.S.A.
Tel 800 733.0404
Fax 510 732.7227
www.cholestech.com

Authorized Representative
AR-MED Ltd
Runnymede Malthouse
Egham TW20 9BD
United Kingdom